To assure the therapeutic utility of dosage units such as tablets, capsules, and solids in single-unit containers, the drug content of each unit in a lot should be distributed in a narrow range around the label strength. For this purpose, there are two tests in pharmacopoeias, the content uniformity test and a simplified alternative test, the mass variation test. The latter can be applied when the variability of drug content is proportional to that of the mass of products as follows: (1) a solution in which active ingredient is perfectly dissolved, (2) solids of active ingredient containing no added substances, (3) freeze-dried solid prepared from true solutions in the final containers, (4) concentration RSD (RSD C ) in the final dosage units is not more than 2%. In the first three cases, the mass of formulation is expected to be perfectly proportional to the content of the active ingredient. In the fourth case, the mass of formulation is regarded as proportional to the content of the active ingredient. In our previous study, 1) the mixing homogeneity at 2% of RSD C was sufficient to maintain the consumer's risk of mass variation test at a low level, the same as in the content uniformity test. The consumer's risk means the risk that consumers purchase defective products. We set the consumer's risk at 5%, and set the quality of defective product at 10% RSD of the content (RSD D ).
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In the case of coating tablets and capsules, the mass variation test is principally applied for inner cores or fillings containing active ingredient. However, the mass variation test is applied to film-coated tablets but not for sugar coated tablets in most pharmacopoeias. At the same time, only in the Japanese Pharmacopoeia, the Mass Variation Test can be applied for hard capsules using whole weight including the capsule shell. The difference among dosage forms in the applicability is based on the natures of the outer crusts of the formulations. However, the applicability of mass variation tests have been decided empirically, and no practical data about the mass variation test of the dosage forms are available. In this study, we investigated the effect of coatings and capsule shells on the results of the mass variation test using the test results of products released in Japan, and assessed the adequacy of application of the mass variation test to coating tablets and capsules.
Theoretical Background In the case of coated tablets and capsules, a formulation consists of two parts: one is the outer covering crusts such as a coating or capsule shell, and the other is the inside core such as core tablets or fillings which usually contain the active ingredient. Therefore, the variations in the whole formulation mass consist of mass variations of these two parts. The relationship of weights of the whole formulation, outer crusts (coating, capsule shell) and inner core (core tablet, filling) are described below,
where w, w O and w I are the individual weight of whole formulation, outer and inner, respectively. Assuming that the individual formulations make up a manufacturing lot, mean and variance of the lot are described as From Eqs. 2, 3 and 4, lot RSD of the inner core weight is (5) and also, the RSD of the outer crust weight is (6) In the case of plain tablets, the following equation is effective,
where RSD D and RSD C are the lot RSDs of dose and concentration, respectively. However, in the case of coating tablets or hard capsules, an ordinary formulation contains an outer coat consisting of an inactive ingredient. Therefore, dose uniformity is described as follows.
where RSD CI is a lot RSD of the concentration of the core containing the active ingredient.
Calculation of Acceptance Values
The acceptance values are used as criteria of the mass variation test in JP14, 2) and are calculated from the standard deviation of drug content estimated and the deviation of mean content from label claims 3, 4) as follows. when the sample size is 30
s: standard deviation of the sample Experimental Forty-nine pharmaceutical companies participated in this study. 1, 5) All products studied were released in Japan and details of the sources of the products are described in ref. 1 . Ten units each were sampled from individual lots. All the brands of sugar-coated tablets were tested using two types of samples; one is a pre-coated plain tablet sampled from production lines, another is a finished sugar-coated tablet. Pre-coated plain tablets of film-coated tablets were tested for one brand.
Measurements were done by the individual manufacturers. The assay methods used were HPLC and UV absorption methods. Analytical precision was below 2.5% of relative standard deviation. The mean and S.D. of drug content, formulation weight and concentration (w/w%) of the active ingredient were calculated for each 10 units in a lot, and were used for obtaining the acceptance values of JP14, as described above. Details of the test procedure of each dosage form in the same as in ref. 1 .
Results and Discussions
Effect of Crusts on RSD W in Commercial Products. Sugar-Coated Tablets Generally, the mass variation test is not applied for sugar-coated tablets because it has been believed that the sugar coating largely affects the variation in tablet weight, and the mass variation may not correctly reflect the content variation. To examine the effect of coatings on the mass variation test, two types of samples were tested: one is a pre-coated plain tablet sampled from production lines, another is a sugar-coated tablet as a final product. In all the dosage forms, sugar-coated tablets showed the largest RSD W ( Table 1 ). The mean RSD W of commercial sugarcoated tablets (2.73%) is about three times those of plain (0.77%) and film-coated (0.85%) tablets, whereas the RSD WI of the pre-coated plain tablets (1.05%) is close to the RSD W of plain tablets. This means that the mass variation test of sugar-coated tablets overestimates the uniformity of mass by using the whole weight instead of the core weight containing active ingredients. In Fig. 1 , the RSD W of sugar-coated tablets correlated well with the RSD WO of sugar coatings, but not with the RSD WI of the core tablets. Coating materials accounted for 44% of the sugar-coated tablets in weight, and showed 6% of RSD WO (Table 1) . It was concluded that the large RSD W of sugar-coated tablets was, as has been believed, caused by the large weight variability of sugar coatings. Therefore, it is difficult to apply the mass variation test to sugar-coated tablets as a releasing test. However, the mass variation test can be applied to pre-coated plain tablets as an in-process test.
Film-Coated Tablets
Though the film-coated tablets showed a high RSD WO of 8%, their RSD W was as low as that of plain tablets ( Table 1 ). The reason for the low RSD W of film-coated tablets was the rather small proportion of coating materials. The film-coated tablets contained about 8% coating material whereas sugar-coated tablets contained almost 50% coating materials. In most pharmacopoeias, the mass variation test is applicable for film-coated tablets but not for sugar-coated tablets. The difference between the two types of coated tablets is the effect of the coating crusts on mass variation. The adequacy of the application of a mass variation test for film-coated tablets was supported by the result that the film coating had little effect on the mass variation.
Hard Capsules The mass variation test of commercial capsules showed slightly smaller RSD W than RSD WI (Table  1) . In contrast, sugar-coated and film-coated tablets showed larger RSD W than RSD WI . The capsule shell accounted for 20% of the formulation weight and showed relatively small RSD WO (2.01%). The noticeable difference between a hard capsule and coated tablets was the considerably small mass variation of the outer shells. Because of the very low variability of capsule shell weight, the JP Mass Variation Test uses the whole capsule weight in the first step of the test, whereas mass variation tests of other pharmacopoeias use only the filling weight. Our results showed that the mass variation is possibly underestimated by using the whole weight of capsules instead of the filling weight. The variance in whole formulation weight is the sum of variances of the inner core and outer crust weights. Therefore, the S.D. of the whole formulation weight is theoretically larger than the S.D. of the filling weight. However, the mass variation test evaluates the RSD W but not the S.D. of weight. Accordingly, the calculated RSD W was reduced by the addition of the shell's weight to filling weight. To avoid the underestimation by the mass variation, the corrected RSD W should be evaluated as described in the previous other section.
Relationship between RSD W , RSD WO and Proportion of Outer Crusts Our results showed that if the whole formulation weight is used to determine inner core weight, mass variation is overestimated for sugar-coated tablets, underestimated for capsules and just estimated for film-coated tablets (Table 1 ). These differences are caused by the difference in the relative weight of outer coatings or shells compared to the whole weight of the products and its variability. Figure 2 shows the relationship between RSD W , RSD WO and the proportion of the outer coating. When m W is 1, from Eq. 4, RSD W is (9) From Eqs. 5 and 6, the following equations are introduced.
From Eqs. 9, 10 and 11, the relationship between RSD W , RSD WO and the proportion of the outer coatings is 
. Contour Plots of Estimation Quality of Mass Variation Test
Gray and dark gray areas show the underestimation, light gray areas show the overestimation in mass variation tests using whole formulation weight. Broken line shows the just-estimated boundary. RSD W was calculated by Eq. 12 under the condition of the RSD WI assumed to be 2.0%.
(12) Figure 2 shows the relationship of Eq. 12 under the condition of the RSD WI assumed to be 2.0%. The position of formulation on the contour map in Fig. 2 could indicate the applicability of the mass variation test. The light gray area in Fig. 2 shows overestimation results, and the gray and dark gray areas show the underestimation results for mass variation tests using whole formulation weight. The broken line in Fig.  2 shows the just-estimated boundary between under-and over-estimation. When the RSD WO is smaller than 2.0%, RSD W is always lower than RSD WI , regardless of the proportion of the coating weight. Therefore, the mass variation is possibly underestimated by using the whole weight of hard capsules, which showed about 2% of RSD WO . The average proportion of the coating weight of the sugar-coated tablets was 44%, and RSD WO was larger than 4%. The position of sugar-coated tablet in Fig. 2 shows that the mass variation test possibly overestimated RSD WI under this condition. In the case of film-coated tablets, the average proportion of the coating weight of film-coated tablets was 7.7%, and RSD WO was 8.1%; Fig. 2 also shows that the mass variation test of film-coated tablets occurs in the vicinity of the just estimated boundary, though the RSD WO is very large. In conclusion, the applicability of coated tablets and capsules depends on the proportion of coating to the whole formulation weight, since there are variations of weight in the coatings, as shown in Fig. 2 .
Adaptive Usage of Mass Variation Tests. Usage of Modified Acceptability Constant The mass variation test can principally be applied for formulations in which the mass is expected to be proportional to the content of the active ingredient. In our previous study, 1) from the standpoint of consumer's risk, it was shown that the RSD C of a product should be below 2% to apply the mass variation test for content uniformity tests. However, even if the product showed an RSD C higher than 2%, it is possible to apply the mass variation test with some modification without an increase in consumer's risk. The modification would be to increase the acceptability constant k (ordinarily 2.2 and 1.9 for the sample size of 10 and 30, respectively) used to calculate the acceptance values for a mass variation test in JP14. 2) As shown in Eq. 7, dose uniformity (RSD D ) consists of mass variation (RSD W ) and mixing homogeneity (RSD C ). If the RSD C can be determined in advance, the appropriate limit (L W ) for RSD W can be set according to the specified limit
The acceptance value of the content uniformity test in JP14 is acceptance valueϹ|MϪX|ϩks (15) and
where X is the mean of content. From Eqs. 13, 15 and 16, the criterion of the test is described as:
where L is the specification limit of the test (normally 15.0). Eq. 17 can be changed to (18) From Eqs. 13 and 18, the following relationship is introduced:
where (21) From Eqs. 7 and 13, the following relationships are introduced:
(23) (24) and from Eqs. 14 and 24, the relationship between L D and L W is described as follows: (25) When modified acceptability constant kЈ is used for the mass variation test, the acceptance value is acceptance valueϭ|MϪA|ϩkЈs W (26) and
The same steps as in Eqs. 16 to 19 about L D , L W are given as: (28) Because A is almost the same as X, from Eqs. 21 and 28, L W is
and from Eqs. 20 and 25 L W is also: (30) accordingly, from Eqs. 29 and 30 the relationship between k and kЈ is described as follows:
When AϭX and A is almost the same as M (ϭ100), Eq. 21 gives:
then Eq. 32 is changed as follows:
The calculated kЈ is shown in Table 2 . The kЈ increases following RSD C increases. When the RSD C is less than 2%, the same acceptability constant as the content uniformity test can be used for the mass variation test. Additionally, modified constant kЈ allowed us to apply the mass variation test under the condition of RSD C being higher than 2%. Figure 3 shows the relationships of the acceptance values between content uniformity and mass variation tests for tested commercial plain and film-coated tablets. When the same acceptability constants k (2.2) as in JP14 were used for content uniformity and mass variation tests, the acceptance constants of the mass variation test is always lower than those of the content uniformity test, and correlation between the two values was therefore not as high. When the modified acceptability constants kЈ corresponding to individual RSD C 's for the mass variation test were used instead of ordinary one, the correlation between the two values was very high (Fig. 3) . Therefore, as a quality control routine, if the RSD C is known previously, the mass variation test can be used as a content uniformity test by using modified acceptability constants kЈ.
Usage of Intact Whole Hard Capsules As described above, the mass variation is possibly underestimated by using the whole weight of the capsules instead of the filling weight. To avoid the underestimation of mass variation, corrected individual estimated contents of the units should be used. This can be achieved by first determining the mean capsule shell weight using empty capsules, and then weighing individual whole capsules. In calculating of acceptance value, individual estimated contents of the units tested (see the paragraph of calculation of acceptance values) are obtained as below:
where W O is the mean capsule shell weight. The criterion for intact hard capsules was the same as the ordinary JP mass variation test. The burdensome procedure of taking off the capsule shells in the mass variation test can be avoided by using the corrected acceptance values.
Conclusion
Differences in the applicability of the mass variation test are caused by differences in the proportion and variability of the weight of outer crusts. It is difficult to apply the mass variation test instead of content uniformity test to sugarcoated tablets, which contain a large amount of coating. In contrast, the mass variation test can be applied to film-coated tablets because the proportion of coating to whole weight was relative small. The JP Mass Variation Test, which uses the whole capsule weight in the first step of the test, underestimates the variability in drug content because it fails to separately calculate the contribution of the shell weight to the results. To avoid the underestimation of mass variation, a corrected acceptance value is useful. Although the mass variation test can principally be applied to formulate weight when the mass is expected to be proportional to the content of active ingredient, some modification of acceptance values enables us to apply the mass variation tests to instances of more variable drug concentration. 
